Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.

Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM.

Am J Cardiol. 2008 Mar 1;101(5):625-30. doi: 10.1016/j.amjcard.2007.10.023. Epub 2007 Dec 21.

PMID:
18308010
2.

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.

Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y.

Am J Cardiol. 2009 Jul 1;104(1):74-81. doi: 10.1016/j.amjcard.2009.02.047.

PMID:
19576324
3.

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.

Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF.

Int J Clin Pract. 2008 Dec;62(12):1959-70. doi: 10.1111/j.1742-1241.2008.01938.x.

PMID:
19166443
4.

Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.

Dishy V, Liu F, Ebel DL, Atiee GJ, Royalty J, Reilley S, Paolini JF, Wagner JA, Lai E.

J Clin Pharmacol. 2009 Apr;49(4):416-22. doi: 10.1177/0091270009332246. Epub 2009 Feb 26.

PMID:
19246721
5.

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.

Paolini JF, Bays HE, Ballantyne CM, Davidson M, Pasternak R, Maccubbin D, Norquist JM, Lai E, Waters MG, Kuznetsova O, Sisk CM, Mitchel YB.

Cardiol Clin. 2008 Nov;26(4):547-60. Review.

PMID:
19031552
6.

Effectiveness and safety of laropiprant on niacin-induced flushing.

Maccubbin DL, Chen F, Anderson JW, Sirah W, McCrary Sisk C, Kher U, Olsson AG, Bays HE, Mitchel YB.

Am J Cardiol. 2012 Sep 15;110(6):817-22. doi: 10.1016/j.amjcard.2012.05.009. Epub 2012 Jun 8.

PMID:
22683042
7.

Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.

Bays HE, Maccubbin D, Meehan AG, Kuznetsova O, Mitchel YB, Paolini JF.

Clin Ther. 2009 Jan;31(1):115-22. doi: 10.1016/j.clinthera.2009.01.010.

PMID:
19243712
8.

Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.

Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y.

J Clin Lipidol. 2012 May-Jun;6(3):235-43. doi: 10.1016/j.jacl.2011.11.004. Epub 2011 Dec 3.

PMID:
22658147
9.

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.

Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz JA, McCrary Sisk C, Radziszewski W, Wagner JA.

Platelets. 2010;21(3):191-8. doi: 10.3109/09537100903521611.

PMID:
20163197
10.

Safety of extended-release niacin/laropiprant in patients with dyslipidemia.

McKenney J, Bays H, Koren M, Ballantyne CM, Paolini JF, Mitchel Y, Betteridge A, Kuznetsova O, Sapre A, Sisk CM, Maccubbin D.

J Clin Lipidol. 2010 Mar-Apr;4(2):105-112.e1. doi: 10.1016/j.jacl.2010.02.002. Epub 2010 Feb 12.

PMID:
21122637
11.

Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.

Kush D, Hu DY, Ye P, Kim HS, Chen E, Sirah W, McCrary Sisk C, Paolini JF, Maccubbin D.

Cardiology. 2009;114(3):192-8. doi: 10.1159/000228585. Epub 2009 Jul 15.

PMID:
19602880
12.

The effects of laropiprant, a selective prostaglandin Dâ‚‚ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.

Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E.

Platelets. 2011;22(7):495-503. doi: 10.3109/09537104.2011.565433. Epub 2011 Apr 28.

PMID:
21526889
13.

Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.

Chen F, Maccubbin D, Yan L, Sirah W, Chen E, Sisk CM, Davidson M, Blomqvist P, McKenney JM.

Int J Cardiol. 2013 Jul 15;167(1):225-31. doi: 10.1016/j.ijcard.2011.12.103. Epub 2012 Feb 4.

PMID:
22305632
14.

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.

Shah S, Ceska R, Gil-Extremera B, Paolini JF, Giezek H, Vandormael K, Mao A, McCrary Sisk C, Maccubbin D.

Int J Clin Pract. 2010 May;64(6):727-38. doi: 10.1111/j.1742-1241.2010.02370.x.

PMID:
20518948
15.

Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.

Schwartz JI, Stroh M, Gao B, Liu F, Rosko K, Zajic S, Meehan AJ, Ruckle J, Lai E, Wagner JA.

Cardiovasc Ther. 2009 Winter;27(4):239-45. doi: 10.1111/j.1755-5922.2009.00104.x.

PMID:
19903187
16.

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.

Bays HE, Shah A, Lin J, McCrary Sisk C, Paolini JF, Maccubbin D.

J Clin Lipidol. 2010 Nov-Dec;4(6):515-21. doi: 10.1016/j.jacl.2010.08.020. Epub 2010 Oct 28.

PMID:
21122699
17.

Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.

Yadav R, France M, Younis N, Hama S, Ammori BJ, Kwok S, Soran H.

Expert Opin Pharmacother. 2012 Jun;13(9):1345-62. doi: 10.1517/14656566.2012.690395. Review.

PMID:
22607011
18.

A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.

Yiu KH, Cheung BM, Tse HF.

Expert Opin Investig Drugs. 2010 Mar;19(3):437-49. doi: 10.1517/13543781003623223. Review.

PMID:
20141348
19.

Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.

Luo WL, Crumley T, Ebel D, Atiee GJ, Royalty J, Johnson-Levonas AO, Wagner J, Lai E.

J Clin Pharmacol. 2010 Nov;50(11):1273-9. doi: 10.1177/0091270009360042. Epub 2010 Jan 27.

PMID:
20107202
20.

Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials.

McKenney J, Bays H, Gleim G, Mitchel Y, Kuznetsova O, Sapre A, Sirah W, Maccubbin D.

J Clin Lipidol. 2015 May-Jun;9(3):313-25. doi: 10.1016/j.jacl.2015.02.006. Epub 2015 Mar 2.

PMID:
26073389

Supplemental Content

Support Center